PATENT
Attorney Docket No. **NLIGHTS-06903**

REMARKS

Claims 1-20 were filed in the accompanying Continuation Application. The above amendment cancels Claims 1-20, and adds new Claims 21-44. As such, Claims 21-44 are currently pending in this Application.

Dated: December 21, 2001

Jason R. Bond
Registration No. 45,439
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608-218-6900

PENDING CLAIMS

21. A method of treatment, comprising:

a) providing:

i) a subject with symptoms of an inflammatory bowel disease, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and crohn's disease, and

ii) a therapeutic composition comprising a biologically active vitamin D compound, wherein said biologically active vitamin D compound is 1α-hydroxyvitamin D_3; and

b) administering a therapeutically effective amount of said therapeutic composition to said subject under conditions such that said symptoms are reduced.

22. The method of Claim 21, wherein said therapeutically effective amount comprises a daily dose of between 0.1 μg and 20 μg per 160 pounds of said subject.

23. The method of Claim 21, wherein said therapeutically effective amount comprises a daily dose of between 0.5 μg and 10 μg per 160 pounds of said subject.

24. The method of Claim 21, wherein said therapeutically effective amount comprises a daily dose of between 3.0 μg and 10 μg per 160 pounds of said subject.

25. The method of Claim 21, wherein said administering is conducted in a continuous manner.

26. The method of Claim 21, wherein said administering is via a transdermal patch.

27. The method of Claim 21, wherein said administering is via a suppository.

28. The method of Claim 21, wherein said administering is via a slow release oral formulation.

29. A method of treatment, comprising:

a) providing:

i) a subject with symptoms of an inflammatory bowel disease, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and crohn's disease, and

ii) a therapeutic composition comprising a biologically active vitamin D compound, wherein said biologically active vitamin D compound is 1α-hydroxyvitamin D_2; and

b) administering a therapeutically effective amount of said therapeutic composition to said subject under conditions such that said symptoms are reduced.

30. The method of Claim 29, wherein said therapeutically effective amount comprises a daily dose of between 0.1 μg and 20 μg per 160 pounds of said subject.

31. The method of Claim 29, wherein said therapeutically effective amount comprises a daily dose of between 0.5 μg and 10 μg per 160 pounds of said subject.

32. The method of Claim 29, wherein said therapeutically effective amount comprises a daily dose of between 3.0 μg and 10 μg per 160 pounds of said subject.

33. The method of Claim 29, wherein said administering is conducted in a continuous manner.

34. The method of Claim 29, wherein said administering is via a transdermal patch.

35. The method of Claim 29, wherein said administering is via a suppository.

36. The method of Claim 29, wherein said administering is via a slow release oral formulation.

37. A method of treatment, comprising:

a) providing:

i) a subject with symptoms of an inflammatory bowel disease, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and crohn's disease, and

ii) a therapeutic composition comprising a biologically active vitamin D compound, wherein said biologically active vitamin D compound is 19-nor-1α,25-dihydroxyvitamin D_2; and

b) administering a therapeutically effective amount of said therapeutic composition to said subject under conditions such that said symptoms are reduced.

38. The method of Claim 37, wherein said therapeutically effective amount comprises a daily dose of between 0.1 μg and 20 μg per 160 pounds of said subject.

39. The method of Claim 37, wherein said therapeutically effective amount comprises a daily dose of between 0.5 μg and 10 μg per 160 pounds of said subject.

40. The method of Claim 37, wherein said therapeutically effective amount comprises a daily dose of between 3.0 μg and 10 μg per 160 pounds of said subject.

41. The method of Claim 37, wherein said administering is conducted in a continuous manner.

42. The method of Claim 37, wherein said administering is via a transdermal patch.

43. The method of Claim 37, wherein said administering is via a suppository.

44. The method of Claim 37, wherein said administering is via a slow release oral formulation.